Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 7Not yet recruiting 3Completed 3Unknown 1Terminated 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 705Carcinoma, Non-Small-Cell Lung 472Prostatic Neoplasms 420Neoplasms 379Multiple Myeloma 261Colorectal Neoplasms 261Lung Neoplasms 248Neoplasm Metastasis 230Melanoma 215Ovarian Neoplasms 191Leukemia, Myeloid, Acute 190Pancreatic Neoplasms 181Squamous Cell Carcinoma of Head and Neck 163Recurrence 146Carcinoma, Renal Cell 144Lymphoma 142Glioblastoma 138Lymphoma, Non-Hodgkin 134Stomach Neoplasms 129Triple Negative Breast Neoplasms 127Carcinoma, Hepatocellular 123Brain Neoplasms 123Leukemia, Lymphocytic, Chronic, B-Cell 122Uterine Cervical Neoplasms 117Head and Neck Neoplasms 117Precursor Cell Lymphoblastic Leukemia-Lymphoma 115Urinary Bladder Neoplasms 113Lymphoma, Large B-Cell, Diffuse 105Sarcoma 102Lymphoma, Follicular 100

Interventions

Gemcitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Interventional × Pancreatic cancer, adult × Clear all
NCT03854110 2025-09-11

Trial to Evaluate Safety and Tolerability of GP-2250 in Combination With Gemcitabine

Geistlich Pharma AG

Phase 1 Active not recruiting
64 enrolled
Gastrointestinal

Pancreatic cancer, adult

Data powered by HemOnc (CC BY 4.0) Colophon âš¡